Tumor Response Evaluation Transarterial Chemoembolization-treated Hepatocellular Carcinoma by Kurniawan, J. (Juferdy)
Volume 17, Number 1, April 2016 1
EDITORIAL
Tumor Response Evaluation 
Transarterial Chemoembolization-treated 
Hepatocellular Carcinoma
Juferdy Kurniawan 
Division of Hepatobiliary, Department of Internal Medicine, Faculty of Medicine  
Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta 
Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate stage 
hepatocellular carcinoma (HCC), as recommended by Barcelona Clinic Liver Cancer (BCLC) 2016 staging 
system. Data showed that patients treated with conventional TACE had longer median survival time (18-28,7 
months) compared to those who did not (9,2-19,7 months).1 However, the clinicians have to select carefully 
which of their patients are suitable for undergoing TACE.2
7KH HI¿FDF\RI7$&(SURFHGXUH FDQEH DVVHVVHGE\ UDGLRORJLF UHVSRQVH ELRORJLF UHVSRQVH DOSKDIHWR
protein), degree of mass necrosis, as well as patient’s survival and quality of life.3,4 Among them, radiologic 
response assessment plays the central role in the evaluation of treatment success following TACE. According to 
PRGL¿HGUHVSRQVHHYDOXDWLRQFULWHULDLQVROLGWXPRUVP5(&,67RU(XURSHDQ$VVRFLDWLRQIRUWKH6WXG\RIWKH
/LYHU($6/FULWHULDUHVSRQVHRI7$&(LVFODVVL¿HGLQWRHLWKHUFRPSOHWHUHVSRQVHSDUWLDOUHVSRQVHSURJUHVVLYH
lesion, or stable lesion.5,6,7 This criteria keeps the concept of measuring the viable part of residual tumor tissue 
and recommended the uni-dimensional assessment of the longest viable tumor diameter in order to determine 
the category.26KLPHWDOGHPRQVWUDWHGDFOHDUSURJQRVWLFVXUYLYDOEHWZHHQWKH¿UVWWZRFULWHULDVZLWKHDFK+5
1 and 2,75, p < 0,001) and the rest ones (HR 6,32 and 16,06, p < 0,001).8
Abdominal multiphasic CT scan or MRI is the common modality used, usually performed 4 weeks after 
TACE. Aside from CT scan and MRI, contrast-enhanced ultrasonography (CEUS) is now recognized as a useful 
imaging tool for evaluating immidiate response after TACE. It facilitates real-time vascular phase imaging of high 
resolution, thus is more effective for showing feeding artery than contrast-enhanced CT or MRI. The use of CEUS 
is also relatively safer since it can be used without risk of nephrotoxicity or ionizing radiation.9,10,11Nevertheless, 
LWUHPDLQVGLI¿FXOWIRU&(86WRH[KLELWFRPSUHKHQVLYHDVVHVVPHQWRIWKHZKROHOLYHUSDUHQFK\PDGXULQJWKH
short duration of the arterial phase. Similar to basic US, poor acoustic window or deep seated lesion results in 
poor imaging. In addition, CEUS is inferior in case of multiple lesions or very large tumor, since they usually 
can’t be captured on single plane.9,11,12
Radiologic evaluation response can be very helpful for the context of follow up and identifying the need 
RIUHWUHDWPHQW$ODFNRIREMHFWLYHUDGLRORJLFUHVSRQVHDIWHUWKH¿UVW7$&(VHVVLRQVKRXOGQRWDXWRPDWLFDOO\
abandon further TACE treatments. Georgiades et al showed that second TACE improved the response found 
in 47% patients with initial unsatisactory result.13 Therefore, patients with viable tumor tissue detected can be 
considered for retreatment with precaution of their clinical tolerance 6-8 weeks after evaluation.14 However, 
the decision for retreatment should not only be taken based on the radiological response as TACE may become 
a double-edged sword for liver function. In this context, objective radiologic tumor response, impairment of 
OLYHUIXQFWLRQDQGOLYHUGDPDJHDIWHUWKH¿UVW7$&(VHVVLRQDUHLQWHJUDWHGLQWRWKHV\VWHPRIWKHDVVHVVPHQW
for retreatment with TACE (ART score).1,15
TACE is currently the mainstay palliative liver-directed treatment modality for intermediate stage HCC. 
Tumor response evaluation may be the best indicator for further treatments need to be taken following TACE.
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